

See discussions, stats, and author profiles for this publication at: <https://www.researchgate.net/publication/341926019>

DIAGNOSTIC PERFORMANCE OF THE RHEUMATOID FACTOR ISOTYPES IN RHEUMATIC DISEASES

Conference Paper in *Annals of the Rheumatic Diseases* · June 2020

DOI: 10.1136/annrheumdis-2020-eular.4039

CITATIONS

0

READS

106

19 authors, including:



Rita Angélica Pineda-Sic

Hospital San Juan de Dios Guatemala

19 PUBLICATIONS 119 CITATIONS

SEE PROFILE



David Vega-Morales

Mexican Institute of Social Security

120 PUBLICATIONS 462 CITATIONS

SEE PROFILE



Leticia Santoyo-Fexas

13 PUBLICATIONS 37 CITATIONS

SEE PROFILE



Ivan de Jesus Hernandez Galarza

Hospital of UANL University

36 PUBLICATIONS 57 CITATIONS

SEE PROFILE

Table 1. RF diagnostic performance in rheumatic diseases

Group	n	Isotype**	Cut-off UR/ml	Significance	AUC (95% CI)	Sensitivity %	Specificity %	Youden Index	Sensitivity %	Specificity %
									Manufacturer cut-off +	Manufacturer cut-off +
RA	22	IgM	135.3	0.06	0.722(0.604 to 0.839)	60%	85.2	0.45	68.2	55.5
Psa	44	IgA	47.2	0.074	0.698(0.553 to 0.842)	54.5	81.8	0.35	54.5	77.3
ASP	44	IgA	39.5	0.080	0.668(0.511 to 0.826)	54.5	88.6	0.43	54.9	79.5
SS	44	IgM	180.6	0.088	0.535(0.088 to 0.708)	54.5	74.4	0.28	68.2	9.3
Healthy	44	IgM	16.3	0.046	0.896(0.806 to 0.986)	77.3	88.9	0.66	68.2	97.8
SLE	41	IgA	42.6	0.073	0.701(0.557 to 0.845)	54.5	85.3	0.39	54.5	73.5
FBM	35	IgM	68.6	0.071	0.752(0.612 to 0.892)	63.6	82.8	0.46	68.2	51.7
OA	38	IgM	48.0	0.053	0.873(0.770 to 0.976)	63.6	96	0.59	68.2	88
PG	20	IgM	117.0	0.076	0.758(0.609 to 0.908)	59.1	89.5	0.49	68.2	63.2
Total	332									

** The isotype with the best AUC for each clinical scenario. + Manufacturer cut-off value: 20UR/ml

FRI0588 DIAGNOSTIC PERFORMANCE OF THE RHEUMATOID FACTOR ISOTYPES IN RHEUMATIC DISEASES

R. Pineda-Sic¹, D. Vega-Morales¹, L. Santoyo-Fexas¹, M. M. Castañeda-Martínez¹, I. D. J. Hernandez-Galarza¹, M. A. Villarreal-Alarcón¹, J. C. Riegatorres¹, L. Pérez Barbosa¹, D. E. Flores Alvarado¹, M. Eguia Bernal¹, G. Serna-Peña¹, D. Á. Galarza-Delgado¹. ¹Universidad Autónoma de Nuevo León, Monterrey, Mexico

Background: Rheumatoid Factor (RF) is used for the classification of Rheumatoid arthritis (RA) in patients whose main complaint is hand arthritis but is well known that other conditions have positive RF. Differences in analytical performance between assays were found in previous studies, there was a poor numerical agreement, and using the cut-off proposed by the manufacturer, variation in sensitivity and specificity can be seen.²

Objectives: To determine the cut-off value for RF with the best diagnostic performance for RA in patients with hand arthritis compared with their main differential diagnoses.

Methods: Descriptive, cross-sectional, diagnostic test study. Sampling size was calculated 2:1, with the area under the ROC curve (AUC): 0.708, power 80% and significance 0.05. Patients with RA, Systemic Lupus Erythematosus (SLE), Osteoarthritis (OA), fibromyalgia (FBM), Polyarticular Gout (PG), Psoriatic Arthritis(Psa), Sjögren Syndrome (SS), Arthralgia suspicious for progression to RA (ASP) and healthy subjects, previously classified with the current criteria by certified rheumatologist were included. EUROINMMUN ® assays for RF isotypes IgA, IgM, IgG were used. ROC curves and Youden index for determining the cut-off with the best sensitivity and specificity for each RF isotype comparing RA with other diseases were used. Statistical analyses were performed with SPSS V.24.

Results: Three hundred and thirty-two serum samples from patients were included, in the other rheumatic diseases different from RA, we found positive RF IgM in 141 (45.5%), 82 (26.5%) IgA and 25 (8.1%) IgG. For each clinical scenario

the cut-off with the best sensitivity and specificity was different from the manufacturer proposed, and isotypes with the best diagnostic performance was not the same for each disease, Table 1. We present the ROC curve for RF isotypes in Figure 1.

Conclusion: In order to improve the diagnosis of Rheumatoid Arthritis, different cut-off points of RF and isotypes should be used.

References:

- [1] Van Hoovels L, Jacobs J, Vander Cruyssen B, Van Den Bremt S, Verschuere P, Bossuyt X. Performance characteristics of rheumatoid factor and anti-cyclic citrullinated peptide antibody assays may impact ACR/EULAR classification of rheumatoid arthritis. *Ann Rheum Dis.* 2018;77(5):667-677. doi:10.1136/annrheumdis-2017-212365
- [2] Van Boekel MAM, Vossenaar ER, Van Den Hoogen FHJ, Van Venrooij WJ. Autoantibody systems in rheumatoid arthritis: Specificity, sensitivity and diagnostic value. *Arthritis Res.* 2002;4(2):87-93. doi:10.1186/ar395.

Disclosure of Interests: None declared

DOI: 10.1136/annrheumdis-2020-eular.4039

FRI0589 CLINICAL ACCURACY OF ANTI-PHOSPHATIDYLSERINE/PROTHROMBIN AND ANTI-BETA2GLYCOPROTEIN I DOMAIN I FOR PREDICTING CLINICAL MANIFESTATIONS OF ANTIPHOSPHOLIPID SYNDROME

M. Radin^{*1}, I. Cecchi¹, S. G. Foddai¹, E. Rubini¹, A. Barinotti¹, S. Sciascia¹, D. Roccatello¹. ¹University of Turin, Turin, Italy

Background: Antiphospholipid antibody (aPL) specificities are increasing, however the best accuracy for predicting the clinical manifestations of the diseases is still under debate.

Objectives: To evaluate the clinical accuracy of aPL specificities both individually and/or in combination, to identify a panel of tests that may provide the best accuracy for predicting clinical manifestations of antiphospholipid syndrome (APS).

Methods: We chart-reviewed patients that presented at San Giovanni Bosco Hospital in the last 5 years who tested persistently positive for at least one aPL[1]. Inclusion criteria comprehended: a) Primary APS(PAPS); b) Secondary APS(SAPS), c)aPL positive asymptomatic and d)Patients with clinical manifestations of APS and either inconsistent previous LA positivity and/or low-medium titers aPL(suspect APS).

Results: A total of 122 patients were included in the study 38 PAPS, 31 SAPS, 23 aPL positive asymptomatic and 30 low titers APS patients). Table1 resumes the main clinical and laboratory characteristics of the patients included in the study. All patients were tested for five aPL: criteria aPL, anti-phosphatidylserine/prothrombin(aPS/PT) and anti-Beta2Glycoprotein I Domain I(β2GPI-D1).

Among the single aPL positivity, β2GPI-D1 showed the best accuracy in predicting the clinical manifestations of APS (AUC 0.639, CI95% 0.539–0.74, p=0.011). Similarly, when investigating the possible combinations of aPL panels, the positivity for aPS/PT IgG/IgM and/or β2GPI-D1 showed the best accuracy in predicting the clinical manifestations of APS (AUC 0.698, CI95% 0.604 –0.793, p<0.001) while triple criteria aPL IgG positivity had the best accuracy for predicting recurrences (AUC 0.720, CI95% 0.569–0.871, p=0.012). Results of the ROC curves are illustrated in Figure 1.

